KEGG   DRUG: D06409Help
Entry
D06409                      Drug                                   

Name
Bevacizumab (genetical recombination) (JAN);
Avastin (TN)
Product
Formula
C6638H10160N1720O2108S44
Exact mass
149104.8407
Mol weight
149196.8162
Activity
Antineoplastic [DS:H00014 H00020 H00031]
Remark
Therapeutic category: 
ATC code: 
Comment
anti-VEGF monoclonal antibody
Target
VEGFA [HSA:7422] [KO:K05448]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04150  mTOR signaling pathway
hsa04370  VEGF signaling pathway
hsa05200  Pathways in cancer  
 
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC07 Bevacizumab
      D06409  Bevacizumab (genetical recombination) (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D06409  Bevacizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines
  PDGF family
   VEGFA
    Bevacizumab
     D06409  Bevacizumab (genetical recombination) (JAN)
Antineoplastics [BR:br08308]
 Molecularly targeted agents
  Monoclonal antibody
   Bevacizumab
    D06409  Bevacizumab (genetical recombination) (JAN)
BRITE hierarchy
Other DBs
CAS: 
216974-75-3
PubChem: 
DrugBank: 
NIKKAJI: 

» Japanese version   » Back

DBGET integrated database retrieval system